VRCDF (Verici Dx) Other Long-Term Liabilities : $0.00 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Other Long-Term Liabilities?

Verici Dx's other long-term liabilities for the quarter that ended in Jun. 2024 was $0.00 Mil.

Verici Dx's quarterly other long-term liabilities declined from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil) but then increased from Dec. 2023 ($-0.00 Mil) to Jun. 2024 ($0.00 Mil).

Verici Dx's annual other long-term liabilities stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil).

Verici Dx Other Long-Term Liabilities Historical Data

The historical data trend for Verici Dx's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Other Long-Term Liabilities Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Long-Term Liabilities	Get a 7-Day Free Trial			-	-	-	-	-

Verici Dx Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Verici Dx Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Verici Dx's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines